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ORIGINAL ARTICLEEarly Activation of Th2/Th22 Inflammatory
and Pruritogenic Pathways in Acute Canine
Atopic Dermatitis Skin Lesions
Thierry Olivry1,2, David Mayhew3, Judy S. Paps1, Keith E. Linder2,4, Carlos Peredo5, Deepak Rajpal6,
Hans Hofland5,7 and Javier Cote-Sierra5,8Determining inflammation and itch pathway activation in patients with atopic dermatitis (AD) is fraught with the
inability to precisely assess the age of skin lesions, thus affecting the analysis of time-dependent mediators. To
characterize inflammatory events occurring during early experimental acute AD lesions, biopsy samples were
collected 6, 24, and 48 hours after epicutaneous application of Dermatophagoides farinae house dust mites to
sensitized atopic dogs. The skin transcriptome was assessed using a dog-specific microarray and quantitative
PCR. Acute canine AD skin lesions had a significant up-regulation of genes encoding T helper (Th) 2 (e.g., IL4,
IL5, IL13, IL31, and IL33), Th9 (IL9), and Th22 (IL22) cytokines as well as Th2-promoting chemokines such as CCL5
and CCL17. Proinflammatory (e.g., IL6, LTB, and IL18) cytokines were also up-regulated. Other known pruri-
togenic pathways were also activated: there was significant up-regulation of genes encoding proteases
cathepsin S (CTSS), mast cell chymase (CMA1), tryptase (TPS1) and mastin, neuromedin-B (NMB), nerve growth
factor (NGF), and leukotriene-synthesis enzymes (ALOX5, ALOX5AP, and LTA4H). Experimental acute canine
house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and
pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test
innovative therapeutics modalities for this disease.
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Atopic dermatitis (AD) is a common, chronic, recurrent, in-
flammatory, and pruritic allergic skin disease that spontane-
ously develops with nearly identical clinical phenotypes in
humans and dogs (Marsella and Girolomoni, 2009). In both
species, the pathogenesis of AD is thought to involve a
multifaceted—often IgE-mediated— immune dysregulation
and skin barrier dysfunction stemming from an increasingly
complex interplay of genetic and environmental factors
(Bizikova et al., 2015; Czarnowicki et al., 2014; Malajian and
Guttman-Yassky, 2015; Mu et al., 2014; Pucheu-Haston
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article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bySeveral studies recently reported microarray-based tran-
scriptome profiles obtained from biopsies of visibly lesional
or nonlesional human (Esaki et al., 2015; Gittler et al., 2012;
Gittler et al., 2013; Saaf et al., 2008; Suarez-Farinas et al.,
2011; Suarez-Farinas et al., 2013a) and canine AD skin
(Plager et al., 2012; Wood et al., 2009). These studies have
provided relevant insights into the inflammatory and struc-
tural changes occurring at the time of acute or chronic AD
skin lesions or after immunomodulating treatment with
cyclosporine (Rozenblit et al., 2014), narrow-band UVB
(Suarez-Farinas et al., 2013b), or the monoclonal antibody
dupilumab (Hamilton et al., 2014). Unfortunately, the
inability to precisely assess the age of biopsied skin lesions in
patients with spontaneous AD potentially limits the validity of
characterizing the immunologic cascade that occurs during
lesion development, especially in situations for which gene
transcription is transient or time dependent.
Alternatively, inducing focal allergic skin reactions via
epicutaneous (i.e., patch test) application of offending aller-
gens in hypersensitive patients permits to study the sequence
of immunologic and skin barrier alterations during AD lesion
genesis and expansion. To our knowledge, only three studies
have reported changes in transcriptome profiles after topical
allergen challenges. These were done after patch testing with
either Malassezia sympodialis (Saaf et al., 2008) or con-
tactants (Correa da Rosa et al., 2015) in humans with AD, or
with house dust mite (HDM) allergens in experimentally
sensitized dogs (Schamber et al., 2014). Although this last
study recently confirmed the expected allergen-induced
up-regulation of proinflammatory immune pathways and
the down-regulation of genes involved in epidermalestigative Dermatology. This is an open access
-nc-nd/4.0/). www.jidonline.org 1961
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1962differentiation and barrier function in sensitized dogs, spe-
cific immunologic changes were not discussed in detail
(Schamber et al., 2014).
Our objectives were to study the activation of early
immunologic and pruritogenic pathways in an HDM-induced
dog acute AD model using mRNA profiling of skin biopsy
samples sequentially obtained after allergen challenge.
RESULTS
Epicutaneous HDM challenges in sensitized dogs elicit
inflammation characteristic of acute AD
Cutaneous inflammation was not visible in any of the eight
dogs before or 6 hours after HDM or control patch applica-
tions; it consisted of mild erythema and edema at 24 and 48
hours after HDM challenges (Figure 1a and b). Eosinophilic
and mononuclear dermal inflammation with focal epi-
theliotropism was detected at the HDM—but not control—
patches after 6 hours in four of eight dogs (50%); it was
strongest in 24- and 48-hours HDM skin biopsy samples from
all dogs (Figure 1c and d). All microscopic inflammation
scores were significantly correlated with their respective
patch test lesion grades (Spearman’s r ¼ 0.42e0.52;
P < 0.05). Importantly, epidermal hyperplasia was very mild
and patchy in the 48-hour skin biopsy samples, thereby
confirming that these HDM challenges led to acute, but not
chronic, atopic skin lesions.
Epicutaneous HDM challenges result in time-dependent
variability in gene transcription profiles
Skin biopsy mRNA microarray data and expression changes
relative to control have been deposited in NCBI’s Gene
Expression Omnibus and are accessible through Gene
Expression Omnibus Series accession number GSE74136;
those determined by quantitative PCR are shown in
Supplementary Table S1 online.Figure 1. Macro- and microscopic skin lesions after HDM challenges. (a) Erythem
scores were significantly higher at 24 hours compared with 6-hour control and HD
epitheliotropism after HDM challenges. The epidermis became only slightly hype
(d) Total (epidermal þ dermal) inflammation scores were significantly higher 24
samples. *P < 0.05; **P < 0.01. Clinical and photomicrograph series are of patc
dust mites.
Journal of Investigative Dermatology (2016), Volume 136Microarray and PCR fold changes of the mRNA of 23 genes
(at the three time points) were significantly correlated
(Spearman r ¼ 0.754, P < 0.0001) (see Supplementary
Figure S1 online); such a correlation validates the
microarray-determined mRNA expression data.
A principal component analysis was performed on the
microarray transcriptome profiles of all biopsy samples.
Except for a single 24-hour chip that was removed because of
aberrant outlying values and failed quality control, tran-
scriptomes from the various time points were generally
clustered, which suggested the occurrence of consistent
biological processes (see Supplementary Figure S2 online).
With a minimum threshold of 1.5-fold change in gene
expression over values from control biopsy samples and less
than 5% Benjamini-Hochberg false discovery rate-corrected
P-values, the number of significantly up-/down-regulated
genes at 6, 24 and 48 hours were 0/90, 104/265, and 710/
445, respectively.
The 20 genes most up- and down-regulated at each time
point based on microarray analysis are listed in
Supplementary Table S2 online. Only 27 genes were signif-
icantly differentially expressed in the HDM-induced skin
lesions at all time points compared with the 6-hour control
samples (see Supplementary Figure S3 and Supplementary
Table S3 online).
Gene ontology categories significantly up-regulated at 6
hours were those of early signaling events (e.g., membrane
receptors, transmembrane transporters, nucleoli), but
there was no significant enrichment, as a category, in
inflammatory and immune genes at this early time point (see
Supplementary Table S4 online). In contrast, gene expression
data from samples collected at 24 and 48 hours after HDM
challenges showed significant enrichments in immune
response genes (see Supplementary Table S4).a became visible 24 and 48 hours after HDM application. (b) Patch test lesion
M patches. (c) Eosinophilic and lymphocytic dermal inflammation with focal
rplastic at the latter time point. Hematoxylin and eosin. Scale bar ¼ 100 mm.
and 48 hours after HDM application compared with those of 6-hour biopsy
hes from the same dog. CI, confidence interval; H, hours; HDM, house
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preferential expression of type 2 cytokine and T helper (Th)
2-promoting chemokines
At the 6-hour time point, the application of HDM to the skin
of these sensitized dogs led to the early—but not significant—
activation of genes coding for the Th2 cytokines IL5 and
IL31, the Th2-promoting chemokine CCL17 (TARC); the Th22
cytokine IL22 gene (Figure 2a, see Supplementary Tables S1
and S2) was significantly up-regulated. In contrast, and to
our surprise, TSLP and IL25 were significantly down-
regulated.
Twenty-four hours after HDM application, the expres-
sions of Th2 and Th22 cytokine genes was markedly up-
regulated, especially those of IL5, IL13, IL31, and IL22,
whereas the expressions of TSLP and IL25 were down-
regulated further. This Th2 bias was corroborated by theFigure 2. Expression of selected relevant cytokine, chemokine, and pruritogeni
encoding genes arranged by dominant function. (b) Expression of selected gene
pruritogen receptors. Genes are arranged by their dominant function or family. C
control samples, and bold lettering denotes statistically significant differences at
(starred), which was generally done when the gene was not present or to verify itsstrong up-regulation of Th2-promoting CC chemokine
genes, which were, in decreasing levels of transcription, as
follows: CCL17 (TARC), CCL5 (RANTES), CCL24 (eotaxin-2),
CCL19 (MIP3-beta), CCL13 (MCP4), CCL8 (MCP2), and
CCL27 (CTACK) (Figure 2a, see Supplementary Tables S1 and
S2).
By 48 hours after starting allergen challenges, there was
further amplification of Th2 (IL4, IL5, IL13, IL31, and IL33),
Th9 (IL9), Th22 (IL22), and pro-inflammatory (LTB, IL6, and
IL18) cytokine gene transcription. The expression of Th2-
promoting chemokines was also intensified, with CCL17
being the most differentially expressed of all genes (Figure 2a,
see Supplementary Tables S1 and S2).
In all these samples, the expression of Th1, Th17, regula-
tory cytokine, and CXC chemokine genes did not change
markedly (Figure 2a, see Supplementary Tables S1 and S2).c genes after HDM challenges. (a) Expression of cytokine and chemokine-
s encoding known pruritogens, enzymes involved in their metabolism, or
olors correspond to the level of relative expression compared with 6-hour
P < 0.05. Fold changes are a combination of data from microarray and PCR
expression using the microarray. h, hours; HDM, house dust mite; Th, T helper.
www.jidonline.org 1963
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1964Allergen challenges lead to the up-regulation of multiple
pruritogenic pathways
In 6-hour HDM patch test skin biopsy samples, the only three
significantly up-regulated noncytokine pruritogenswere genes
encodingNGF (NGF) and enzymes involved in leukotriene-B4
(LTB4) synthesis (5-lipoxygenase [ALOX5] and its acti-
vating protein FLAP [ALOX5AP]) (Figures 2b and 3, see
Supplementary Tables S1 and S2).
The Th2 cytokine gene IL31 was the most highly tran-
scribed pruritogen 24 hours after challenge. At that time
point, other significantly up-regulated pruritogenic genes
encoded the 5-lipoxygenase complex, the proteases
cathepsin S (CTSS) and C (CTSC), chymase (CMA1) and the
tryptic peptidase mastin, the bombesin NMB (NMB), and
TrkA (NTRK1), the NGF receptor (Figures 2a and b and
Figure 3, see Supplementary Tables S1 and S2).
After 48 hours, there were few additional changes in pru-
ritogen gene up-regulation compared with the 24-hour
samples, except for the significant transcription increases in
mast cell tryptase TPS1, the pruritogenic cytokines IL4 and
IL6, and genes encoding two enzymes involved in histamine
metabolism: histidine decarboxylase (HDC) and histamine
N-methyltransferase (HNMT) (Figures 2a and b and Figure 3,
see Supplementary Tables S1 and S2).
Acute experimental AD skin lesions are associated with few
epidermal changes
In this canine acute atopic skin lesion model, the expression
of genes encoding epidermal differentiation and stratum
corneum barrier genes was generally not significantly
changed (see Supplementary Tables S1 and S2). Notable
exceptions were the down-regulation of coding for claudin-1
(CLDN1), ELOVL fatty acid elongase 6 (ELOVL6), and
sphingosine-1-phosphate lyase 1 (SGPL1) and the up-
regulation of the proliferating cell nuclear antigen (PCNA),
serpin peptidase inhibitor B4 (SERPINB4), and histidine
ammonia-lyase (histidase, HAL) genes. The transcription of
genes encoding the calcium-binding proteins S100A8,
S100A9, and S100A12 was down-regulated at the 6-hour
time point before being increasingly up-regulated over
time, with the most significant changes occurring 48 hours
after challenge (see Supplementary Table S1).Figure 3. Expression of selected
pruritogenic genes after HDM
challenges. In this word cloud are
only represented genes with a
significantly greater than 1.5-fold
change in gene expression in HDM
compared with control samples. The
size is proportional to the level of
expression, the color corresponds to
that of the pathway involved, and an
underlined name denotes a down-
regulation of this gene. h, hour; HDM,
house dust mite.
Journal of Investigative Dermatology (2016), Volume 136Allergen challenge is not associated with very early
immune dysregulation
To determine if some of the genes might have been up-
regulated earlier than what was seen in the 6-hour biopsy
samples, the expressions of 14 selected genes perceived to be
of importance were quantified by PCR in a second experi-
ment in which biopsy samples were taken 1 hour and 3 hours
after allergen challenge.
Except for TNF, which was significantly up-regulated as
early as 1 hour after HDM challenge, the expression of
the other genes was not significantly changed (see
Supplementary Table S5 online).DISCUSSION
In this article, we establish that, in an experimental HDM-
sensitized dog model, acute AD skin lesions develop soon
after epicutaneous allergen challenge and exhibit the
expected Th2 and Th22 cytokine bias. Furthermore, induced
lesions are associated with the activation of several itch-
promoting pathways, which include known pruritogenic cy-
tokines such as IL31, cathepsins and mast cell proteases,
NGF, NMB, and enzymes involved in LTB4 and histamine
synthesis.
The predominant increase in the expression of Th2 cyto-
kine genes seen in this model mirrors that found in the
transcriptome of acute—but not chronic—human AD skin
(Gittler et al., 2012). We did not detect the small up-
regulation of Th1 and Th17 cytokines seen in chronic hu-
man AD lesions, however (Gittler et al., 2012); this difference
might be due to the early postchallenge biopsy times in this
study, which reflects early acute atopic lesion development
but not chronic AD. This existing Th2 cytokine bias of canine
AD and experimental HDM-induced skin lesions has been
known for over a decade (Marsella et al., 2006; Nuttall et al.,
2002; Olivry et al., 1999). Our study confirms the stronger
up-regulation of IL13 and IL5 over that of the classic Th2
cytokine, IL4, as previously shown in spontaneous canine AD
skin (Schlotter et al., 2011), after HDM patch testing in
sensitized dogs (Marsella et al., 2006), or after stimulation of
T lymphocytes collected from canine chronic AD skin
(Jassies-van der Lee et al., 2014).
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transcription of IL31 after allergen challenge; in fact, IL31 was
the genemost up-regulated in the 6- and24-hour samples, and it
was second in expression to CCL17, 48 hours after allergen
provocation. This cytokine, a strong pruritogen in dogs as in
other species (Gonzales et al., 2013), is also highly expressed in
acute and chronic human AD skin (Gittler et al., 2012).
Although IL-31 had previously been detected in the serum of
half of atopic dogs (Gonzales et al., 2013), it was not found to be
transcribed in the lesional skin of dogs with AD using PCR
(Mizuno et al., 2009). The clear Th2 cytokine bias seen in these
acute canine AD lesions was likely enhanced by the preferen-
tial—and often strong—up-regulation of CC chemokines that
recruit cells involved in a type 2 immune response. In fact,
CCL17 was the highest-expressed gene in microarray and PCR
assays at the 48-hour time point. This strong up-regulation of
CCL17 has been previously reported in lesional human (Choy
et al., 2012; Gittler et al., 2012) and canine AD skin (Maeda
et al., 2002; Maeda et al., 2005; Plager et al., 2012), as well as
after HDM challenges in sensitized dogs (Marsella et al., 2006).
In this study, a significant expression of IL22 was found as
early as 6 hours after allergen provocation; this was the only
cytokine up-regulated at that early time point. This cytokine-
encoding gene has been similarly found to be activated in the
skin of humans with acute and chronic AD (Gittler et al.,
2012; Nograles et al., 2009), especially that of patients
with the intrinsic form of the disease (Martel et al., 2016).
Furthermore, skin-homing IL-13e and IL-22eproducing Th2/
22 and Tc2/22 (i.e. type 2/22 cytotoxic T-cells) were recently
found to be elevated in people with AD, and their numbers in
the peripheral blood correlated with skin lesion scores and
IgE levels (Czarnowicki et al., 2015). Such increase in IL22
has been reported in stimulated T lymphocytes collected
from both nonlesional and lesional chronic AD canine skin
(Jassies-van der Lee et al., 2014). IL-22 might participate in
the promotion of AD chronicity, because it induces
epidermal hyperplasia, inhibits proteins involved in
epidermal differentiation and skin barrier function, and up-
regulates antimicrobial peptides that include S100A8 and
S100A9; the latter were also highly expressed in our study
(Eyerich et al., 2009; Wang and Xu Landen, 2015).
In this article, we document the significant up-regulation of
the gene for the Th2-promoting cytokine IL9 and two of its
transcription factors (SPI1 and BATF), after allergen challenge
in atopic dogs. This cytokine appears important for the pro-
motion of IL-13, IL-17, and IFN-g production by skin-homing
T lymphocytes (Schlapbach et al., 2014). The importance and
the specific role of IL-9 in the pathogenesis of human AD are
currently being investigated (Ciprandi et al., 2013; Ma et al.,
2014).
As recently shown in another HDM patch test study in dogs
(Schamber et al., 2014), the Th2-promoting cytokine gene
IL33 was also up-regulated in our study. This cytokine and its
receptor are also overexpressed in human lesional AD skin
and after HDM patches in sensitized mice; in the latter, it is
activated earlier than in dogs after allergen challenge
(Savinko et al., 2012; Savinko et al., 2013). IL-33 might
participate in the induction of IL-5 and IL-13 production by
type 2 lymphocytes (Th2) and innate lymphoid cells (ILC2)
(Imai et al., 2013; Lott et al., 2015).In the skin of dogs with AD and after the challenge of
canine keratinocytes with HDM allergens, the Th2-promoting
cytokine gene TSLP was found to be up-regulated
(Klukowska-Rotzler et al., 2013). A strong immunostaining
for TSLP was also seen focally in spontaneous canine AD
lesional skin (our unpublished results). In contrast to these
observations, we found the TSLP gene to be down-regulated
as early as 6 hours after allergen provocation in mite-
sensitized dogs. In human AD skin, there is a similar
discrepancy between the lack of significant up-regulation of
TSLP in acute or chronic AD skin (Gittler et al., 2012) and the
strong epidermal immunostaining for this protein that was
initially reported in human AD lesions (Soumelis et al.,
2002). The reasons for this inconsistency are not known,
but the hypothesis that an increase in the transcription of
TSLP could be precocious yet transient was invalidated,
because we did not detect such up-regulation in biopsy
samples collected 1 and 3 hours after HDM application in
our sensitized dogs. Alternatively, the observed down-
regulation of TSLP might be that of the constitutively
expressed anti-inflammatory short isoform of TSLP rather
than that of its proinflammatory long isoform; this has been
shown recently in human AD (Fornasa et al., 2015). The
carboxy-terminal PCR probe used in our study unfortunately
did not allow for the differentiation in the transcription of
either TSLP isoform.
When looking at the expression of pruritogens in this acute
canine AD model, we found the early activation of genes
encoding several proteins known to induce itch, such as Th2
cytokines, several proteases, enzymes involved in the syn-
thesis of leukotrienes, the bombesin NMB, and NGF.
Th2 cytokines shown to directly induce itch are IL-4, IL-13,
and IL-31, as well as TSLP, but a pruritogenic role is only
suspected for IL-2 and IL-6 (reviewed in Storan et al., 2015).
Recently, IL-33 was also found to indirectly induce itch via
mast cell degranulation and histamine release in transgenic
mice (Imai et al., 2013). All of these cytokine genes, except
TSLP, were found to be markedly up-regulated in our dog
model of HDM-induced acute AD; the early and particularly
strong expression of IL31 was especially remarkable. It is
suspected that these Th2 cytokines are involved in the genesis
of atopic itch because of the strong antipruritic effect seen
with the new Janus kinase inhibitor oclacitinib in atopic dogs
(Cosgrove et al., 2013); this drug preferentially blocks Janus
kinase-1emediated signal transduction after binding of the
pruritogenic cytokines IL-2, IL-4, IL-6, IL-13, and IL-31—and
at least theoretically TSLP—to their respective receptors
(Gonzales et al., 2014). That IL-31 is likely responsible for the
generation of clinical signs of canine and human AD is
supported by the recent demonstration of substantial relief of
pruritus manifestations after injection of therapeutic mono-
clonal antibodies targeting IL-31 in dogs (Michels et al.,
2015) or the IL-31 receptor A in humans with this disease
(Nemoto et al., 2015). In atopic dogs, this monoclonal anti-
body also reduces the severity of skin lesions, albeit with a
smaller magnitude than that of itch (Michels et al., 2015).
In this dog model, HDM induced the up-regulation of
genes coding for three mast cell proteases that could be
involved in itch induction: chymase, tryptase, and the
tryptase-like mastin; the latter being analogous to mouse mastwww.jidonline.org 1965
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1966cell protease-11 (Prss34) (note that their human homolog is
only a pseudogene). Mastin has been shown previously to be
up-regulated in acute canine AD skin (Plager et al., 2012),
but its itch-inducing effect has not been studied in animal
species in which this protein exists. Chymase has been shown
to be a pruritogen in a single old publication (Hagermark
et al., 1972). Although intradermal injections of tryptase
induce itch in mice (Ui et al., 2006), they do not appear to do
so in dogs (Carr et al., 2009).
We observed in this study the significant up-regulation of
the pruritogenic cathepsin S, a cysteine protease secreted by
keratinocytes after stimulation by proinflammatory cytokines
such as tumor necrosis factor-a and IFN-g (Schonefuss et al.,
2010). Even though it was first believed to induce itch via
activation of protease-activated receptors (PAR)-2 and -4
(Reddy et al., 2010), it is now known to do so, not by means
of PARs, but by the direct activation of MrgprC11 after spe-
cific cleavage of its aminoterminus (Reddy et al., 2015).
Although cathepsin S was not detected in the lesional
epidermis of NC/Nga mice with AD (Schonefuss et al., 2010),
transgenic mice overexpressing this protein spontaneously
develop a chronic AD-like dermatosis (Kim et al., 2012). The
expression of CTSS was previously found to be significantly
higher in lesional than nonlesional canine AD skin (Plager
et al., 2012). Altogether, cathepsin S might be relevant for
the induction of atopic skin inflammation and/or its associ-
ated itch; the demonstration of its importance awaits trials
with interventions specifically targeting this protease.
The bombesin NMB, whose gene was previously shown to
be up-regulated in lesional acute canine AD skin (Plager
et al., 2012), was also overexpressed early after allergen
challenge in our study. NMB induces itch when injected
intrathecally in rats (Sukhtankar and Ko, 2013). It is possible,
at least theoretically, that NMB could be secreted by primary
afferent neurons and induce mast cell degranulation and
histamine release, as shown for the other mammalian
bombesin, gastrin-releasing peptide (Andoh et al., 2011).
Whether or not NMB is a skin pruritogen, directly or indi-
rectly via mast cell degranulation, has not yet been shown in
any species, to our knowledge.
Of interest was the observation that genes encoding LTB4
synthesis enzymes were among the first to be up-regulated
after allergen challenge. This leukotriene has long been
known to be present in high concentrations in the lesional
skin of dogs and humans with AD (Kietzmann, 1990; Ruzicka
et al., 1986). Intradermal injections of LTB4 variably induce
pruritus in mice (Andoh and Kuraishi, 1998), whereas in-
jections in human skin are mostly not pruritogenic (Camp
et al., 1983). This leukotriene appears involved in the pruri-
tus present in NC mice with chronic AD (Andoh et al., 2011),
and a positive correlation has been found between LTB4
concentrations and pruritus in atopic dogs (Kietzmann,
1990). Whereas the use of the 5-lipoxygenase inhibitor
zileuton appears to have some antipruritic effect in humans
with AD (Woodmansee and Simon, 1999), the clinical
benefit of interventions targeting leukotrienes in atopic dogs
appears minimal (Olivry et al., 2010).
In this study, the only known cytokine pruritogen gene
significantly up-regulated in 6-hour biopsy samples was
NGF. This neurotrophin has been shown to sensitize nervesJournal of Investigative Dermatology (2016), Volume 136to nonehistamine-induced itch, especially that induced by
cysteine protease-containing cowhage spicules (Rukwied
et al., 2013). In humans with AD, the immunoreactivity of
NGF is higher in lesional than nonlesional AD and healthy
skin (Dou et al., 2006); its expression is also high in kerati-
nocytes from atopic patients, and it appears to be directly
responsible for neurite outgrowth (Roggenkamp et al., 2012).
In contrast to these observations, the dermal concentration of
NGF was reported to be lower in microdialysates of nonle-
sional and lesional AD than in healthy human skin (Papoiu
et al., 2011). A possible explanation for this discrepancy
might be that NGF is only transiently expressed during a flare
of AD because, in our study, it was up-regulated early before
being down-regulated in samples collected 48 hours after
allergen challenge.
This study of the skin transcriptome that occurs early after
epicutaneous HDM allergen challenge in sensitized dogs
showed the early expression of Th2/Th22 cytokines and
proteases as well as other known noncytokine pruritogens.
Because this model recapitulates many of the molecular
events seen in acute human AD, it could be used to test new
therapeutics developed to treat atopic itch and skin lesions in
humans or dogs. These observations should ideally be
confirmed with studies of corresponding protein expression
and with a higher number of animals (especially for the study
of early time points after allergen challenge). Nevertheless,
our results suggest that atopic itch is likely due to the com-
bined action of multiple pruritogens. As a result, the suc-
cessful treatment of existing and active pruritic AD skin
lesions is likely to require the use of drugs with broad targets
rather than the specific inhibition of single molecules or
pathways. In contrast, the prevention of flares might benefit
from the identification, and subsequent targeting, of early
mediators activating downstream pro-allergic pathways.
MATERIALS AND METHODS
All the experiments involving animals herein were approved by the
institution’s animal care and use committee; animal studies were not
terminal.
Animals
Eight Maltese-beagle atopic dogs (five intact males, three intact
females; 5.5e10.5 years old), epicutaneously sensitized to Derma-
tophagoides farinae HDM (Olivry et al., 2011), were selected after
demonstration of acute AD skin lesions after epicutaneous HDM
challenge. This number of dogs was deemed sufficient for this
experiment to have a 100% power to detect a significant 2-fold
difference in values (mRNA transcription or cell counts) between
pre- and postchallenge skin biopsy samples.
HDM patch tests
To avoid the skin irritation seen with adhesives surrounding small
patches, allergen challenges were done with slight modification of
our previously reported method (Olivry et al., 2012). Herein,
allergen challenges consisted of 500 mg of HDM slurry in 10 ml of
mineral oil covered by 4  1.5ecm bands of laboratory film (Par-
afilm M laboratory film, Pechiney Plastic Packaging, Chicago, IL)
then covered with waterproof tape at least 2 cm away from the HDM
application sites.
In the first experiment, one mineral oil control and three HDM
patches were placed on the lateral thorax of each of the eight dogs.
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hour after removing patches 6 (HDM and control), 24 (HDM), and
48 hours (HDM) after application using a 4-point scale, as done
previously (Olivry et al., 2006). After heavy sedation and local
anesthesia, skin biopsy samples were collected at each time point.
They were bisected; one half was placed in neutral buffered
formalin, and the other was disposed in RNALater (Ambion, Austin,
TX) and kept frozen until mRNA extraction.
To detect even earlier mRNA expression changes, HDM patches
were later applied onto the thoracic skin of four of the original eight
HDM-sensitized dogs (all intact males, 7 years old). At 1 and 3 hours
after HDM application, patches were removed; macroscopic skin
lesions were then graded, and biopsy samples were collected as
described.
Histopathology
One 5-mm section of each formalin-fixed paraffin-embedded skin
biopsy sample was stained routinely with hematoxylin and eosin.
The entire section was examined, in a manner blinded to the biopsy
timing and patch nature; epidermal, dermal, eosinophilic, and
mononuclear dermal inflammation were graded subjectively as
none (0), mild (1), moderate (2), or severe (3). Epidermal and dermal
scores were also added to yield a score reflecting total inflammation.
Macro- and microscopic lesions were compared between control
and 6-, 24-, and 48-h HDM patches by repeated-measure analysis of
variance (Friedman test) and subsequent posttests (Dunn’s multiple
comparison tests). Nonparametric correlations were done by
calculation of Spearman’s coefficients.
Microarray analysis
Skin biopsy samples disposed in RNALater were minced and placed
in a Precellys homogenizer. Total mRNAwas extracted using Qiagen
RNeasy kit (Qiagen, Valencia, CA) and quantified by NanoDrop
(Thermo Fisher Scientific, Waltham, MA). Samples were normalized
to the lowest concentration sample, and cDNA was made using
Superscript Vilo cDNA synthesis Master Mix (Invitrogen Life Tech-
nologies, Grand Island, NY).
The cDNA samples were then labeled with biotin with the
FL-Ovation cDNA Biotin Module V2 and hybridized to a Canine
Genome 2.0 Array using a Genechip Hybridization Kit. The micro-
array chips were washed and stained using a Genechip Hybridiza-
tion Wash and Stain Kit and then scanned using a Genechip Scanner.
All reagents and readers were used according to the manufacturer’s
instructions (Affymetrix, Santa Clara, CA).
The microarray gene expression data were analyzed using
ArrayStudio 7.0 (OmicSoft, Cary, NC). Data were normalized using
robust multiarray averaging and scaled to a mean target intensity of
150. Differentially expressed transcripts were identified using a
Student t test to compare each challenged time point with the un-
challenged control. Significance thresholds were set at a Benjamini-
Hochberg false discovery rate of 5% and at least a 1.5-foldechange
difference.
Quantitative PCR analysis
To obtain mRNA expression levels for selected genes of interest that
were not assessable with the chosen Affymetrix canine chip, quan-
titative PCR was performed on an Applied Biosystems Viia7 System
(Carlsbad, CA) using Taqman Fast Advanced Master Mix (Invitrogen),
the previously prepared cDNA, and the primer/probe sets reported
in Supplementary Table S6 online. The relative expression levels ofmRNA were determined using the DDCt formula; fold changes were
calculated as 2eDDCt.
To verify the validity of the data obtained with the Affymetrix
microarray, the expression levels of 23 genes with high and low
microarray up- and down-regulation were also tested by quantitative
PCR. The correlation between microarray and PCR fold changes of
mRNA of all genes at the three time points was calculated using
Spearman rank correlation coefficient.
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